[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640608":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":39,"centralContacts":43,"locations":48,"responsibleParty":63,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":83,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"St. Jude Children's Research Hospital","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Childhood Cancer Survivors",null,"Adult survivors enrolled in SJLIFE with prior exposure to cancer treatments associated with increased risk for ASCVD, including chest radiation, neck radiation, and\u002For platinum-based chemotherapy.",[13,14,15,16],"Diagnostic Test: Coronary Artery Calcium Scan","Diagnostic Test: Carotid Artery Ultrasound","Diagnostic Test: Lipoprotein(a) Measurement","Diagnostic Test: Vascular Function Testing",{"label":18,"type":10,"description":19,"interventionNames":20},"Community Controls","Adult community control participants enrolled in SJLIFE without a history of cancer, frequency matched to survivors by age and sex.",[13,14,15,16],[22,27,31,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DIAGNOSTIC_TEST","Coronary Artery Calcium Scan","Low dose, ECG gated, non contrast cardiac computed tomography (CT) scan performed to quantify coronary artery calcium using the Agatston scoring method for assessment of subclinical coronary atherosclerosis.",[9,18],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Carotid Artery Ultrasound","Bilateral high resolution B mode carotid ultrasound with color and spectral Doppler interrogation of the common carotid artery, carotid bulb, and internal carotid artery to assess carotid plaque, stenosis, and intima-media thickness.",[9,18],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Lipoprotein(a) Measurement","Peripheral blood draw for measurement of serum lipoprotein(a) levels to identify ASCVD risk enhancing factors.",[9,18],{"type":23,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Vascular Function Testing","Non invasive vascular function assessments including pulse wave velocity, augmentation index, and arterial elasticity using FDA cleared devices (e.g., SphygmoCor XCEL and HDI\u002FPulseWave CR-2000) to evaluate arterial stiffness and vascular health.",[9,18],[40],{"name":41,"affiliation":5,"role":42},"Stephanie B Dixon, MD, MPH","PRINCIPAL_INVESTIGATOR",[44],{"name":41,"role":45,"phone":46,"phoneExt":10,"email":47},"CONTACT","888-226-4343","referralinfo@stjude.org",[49],{"facility":5,"status":10,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Memphis","Tennessee","38104","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-90.04898,35.14953,{"lat":59,"lon":58},[62],{"name":41,"role":45,"phone":46,"phoneExt":10,"email":47},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100640608","clinical-assessment-and-targeted-imaging-to-characterize-high-risk-atherosclerotic-cardiovascular-disease-of-survivors-in-sjlife-100640608",false,"NCT07594392","Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE","Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in the St. Jude Lifetime Cohort (SJLIFE)","Inclusion Criteria:\n\n\\- SJLIFE Survivor or Control\n\n* Age ≥18 years\n* Enrolled in the St. Jude Lifetime Cohort (SJLIFE)\n* Participant or legal guardian\u002Frepresentative is able and willing to give informed consent.\n\nSJLIFE Survivor only\n\n* Participant has been treated with at least one of the following cancer therapies:\n\nplatinum chemotherapy, neck radiation exposure of at least 1000 centigray (cGy), or chest radiation exposure of at least 1000 cGy (with potential exposure to the heart).\n\nExclusion Criteria:\n\nSJLIFE Survivor or Control\n\n* Previous stroke or intervention for severe carotid arterial disease including carotid endarterectomy or carotid angioplasty and stent placement.\n* Previous myocardial infarction or intervention for severe cardiovascular disease including Coronary Artery Bypass Graft (CABG), coronary stent placement or coronary angioplasty.\n* History of aortic valve replacement\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n\nControl Only\n\n* First degree relative of SJLIFE Survivor\n* History of cancer","ALL","18 Years",{"count":75,"type":76},650,"ESTIMATED","OBSERVATIONAL","Childhood cancer survivors are at increased risk for premature atherosclerotic cardiovascular disease (ASCVD) due to cancer treatment-related exposures, including radiation therapy and platinum-based chemotherapy. Current ASCVD risk assessment tools may underestimate cardiovascular risk in younger survivors. This observational study performs detailed cardiovascular phenotyping using imaging, blood-based biomarkers, and vascular function testing among adult survivors enrolled in the St. Jude Lifetime Cohort (SJLIFE), with comparison to community controls, to better characterize subclinical ASCVD risk and inform survivor-specific prevention strategies.\n\nPrimary Objective:\n\nPerform deeper phenotyping of SJLIFE participants at treatment-related risk of atherosclerotic cardiovascular disease \\[ASCVD\\] to facilitate early detection of pathophysiological targets appropriate for remediation.\n\nSecondary Objectives:\n\nDetermine the distribution of lipoprotein (a) levels and prevalence of elevated levels among survivors with any treatment related exposure-based risk for ASCVD overall and then compared to community controls.\n\nEvaluate prevalence of clinical and imaging markers of ASCVD risk among survivors exposed only to platinum chemotherapy and compare that to community controls.",[80],"Atherosclerotic Cardiovascular Disease",[9,82],"ASCVD","NOT_YET_RECRUITING","2026-05-19",{"date":86,"type":87},"2026-05-22","ACTUAL",{"date":89,"type":76},"2026-06",{"date":91,"type":76},"2031-06",{"name":5,"class":6},1]